CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio

About this update from Cannabis Bioscience International Holdings, Inc.

[{"type":"text","content":"Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.","length":443,"tagName":"p"},{"type":"text","content":"CBIH clarifies that this communication reflects a serious corporate and executive planning approach intended to protect business value and accelerate operational execution. The Company believes that, without adequate working capital, scaled sales, and a sustained product launch into the market, the risks of competitive lag increase, the capacity to convert research into recurring revenue is constrained, and the organization becomes exposed to operational frictions that may affect continuity and growth.","length":507,"tagName":"p"},{"type":"text","content":"If completed, the proceeds would be used primarily to enable and execute an integrated plan that includes, among other corporate purposes: (i) the commercial launch and expansion of CBIH's product portfolio—including VitaCookies, ointments, tinctures, and capsules; (ii) strategic costs associated with the protection, maintenance, and defense of the Company's intellectual property and patent portfolio; and (iii) the costs to establish, deploy, and scale CBIH's statewide educational programs, including the infrastructure and execution required for implementation.","length":579,"tagName":"p"},{"type":"text","content":"In parallel, CBIH continues to execute an agenda of alliances and coordination with ecosystem participants including technical teams, healthcare organizations, and institutional counterparties with the objective of converting interest into verifiable work plans, strengthening operational capabilities, compliance, and quality standards oriented toward results.","length":361,"tagName":"p"},{"type":"text","content":""This evaluation is not about headlines; it is about execution discipline and the protection of corporate value," said Rebeka Lopez, CPA, Director of Finance at CBIH. "Our objective is to enable working capital to bring products to market in...

More updates from Cannabis Bioscience International Holdings, Inc.